The firm expects a promising treatment for acute leukemia could drive upside for the stock.
A promising treatment for acute leukemia makes Syndax Pharmaceuticals an attractive stock, JPMorgan said. Analyst Anupam Rama initiated coverage of Syndax with an overweight rating ahead of what could be significant new data on the company's cancer therapy called revumenib.
The analyst is anticipating key data on revumenib from the ongoing AUGMENT-101 study into relapsed leukemia populations to start coming out in the third quarter of 2023, which could drive upside for the stock, according to the note. "Our peak sales estimate for revumenib of ~ $1.3BWW is at the mid-point / slight higher end of the Street peak sales range and probability of success at the higher end of the Street range," read the note.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
Tubelis scores 21, No. 5 Arizona beats Arizona State 69-60Azuolas Tubelis scored 21 points, Oumar Ballo had 12 points and 12 rebounds, and No. 5 Arizona withstood a second-half comeback by Arizona State for a 69-60 victory Saturday.
Les mer »
STOCK MARKET NEWS: Markets closed, 2023 oil gains, gas higher, Musk's next Twitter File releaseReport: Oil gains minimal in 2023, next Twitter File focus on Fauci. FOX Business is providing real-time updates on the markets, commodities and all the most active stocks on the move.
Les mer »
More than 60 people rescued from Ferris wheelVideo from the park shows sparks coming from a section of The Wheel on New Year’s Eve.
Les mer »
Prince Harry tells 60 Minutes about his decision to speak publiclyPrince Harry tells 60Minutes he's tried to keep his conversations with the British royal family private, but to combat stories in the tabloids, he's been forced to make his concerns public.
Les mer »
More than 60 people rescued from Ferris wheelVideo from the park shows sparks coming from a section of The Wheel on New Year’s Eve.
Les mer »